ECSP066751A - Piperidinilcarbonil-pirrolidinas y su uso como agonistas de melanocortina - Google Patents

Piperidinilcarbonil-pirrolidinas y su uso como agonistas de melanocortina

Info

Publication number
ECSP066751A
ECSP066751A EC2006006751A ECSP066751A ECSP066751A EC SP066751 A ECSP066751 A EC SP066751A EC 2006006751 A EC2006006751 A EC 2006006751A EC SP066751 A ECSP066751 A EC SP066751A EC SP066751 A ECSP066751 A EC SP066751A
Authority
EC
Ecuador
Prior art keywords
agonists
pirrolidinas
piperidinilcarbonil
melanocortine
processes
Prior art date
Application number
EC2006006751A
Other languages
English (en)
Inventor
David Hepworth
Andrew Anthony Calabrase
David Sebastien Fradet
Mark Lansdell
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34864830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066751(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0412417A external-priority patent/GB0412417D0/en
Priority claimed from GB0425530A external-priority patent/GB0425530D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP066751A publication Critical patent/ECSP066751A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

La presente invención se refiere a una clase de agonistas de melanocortina CR4 de fórmula general (I) (consta gráfico) en la que R1, R2, R3, R4 y R5 son como se han definido anteriormente y especialmente a compuestos agonistas selectivos de MCR4, a su uso en medicina, a composiciones que los contienen, a procesos para su preparación y a intermedios usados en tales procesos
EC2006006751A 2004-02-04 2006-08-03 Piperidinilcarbonil-pirrolidinas y su uso como agonistas de melanocortina ECSP066751A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0402492.3A GB0402492D0 (en) 2004-02-04 2004-02-04 Pharmaceutically active compounds
GB0412417A GB0412417D0 (en) 2004-06-03 2004-06-03 Pharmaceutically active compounds
GB0425530A GB0425530D0 (en) 2004-11-19 2004-11-19 Pharmaceutically active compounds

Publications (1)

Publication Number Publication Date
ECSP066751A true ECSP066751A (es) 2006-11-16

Family

ID=34864830

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006751A ECSP066751A (es) 2004-02-04 2006-08-03 Piperidinilcarbonil-pirrolidinas y su uso como agonistas de melanocortina

Country Status (25)

Country Link
EP (1) EP1716135B1 (es)
JP (1) JP4031814B2 (es)
KR (1) KR100830763B1 (es)
CN (1) CN1930146A (es)
AP (1) AP2006003699A0 (es)
AR (1) AR048232A1 (es)
AT (1) ATE511507T1 (es)
AU (1) AU2005213538A1 (es)
BR (1) BRPI0507435A (es)
CA (1) CA2555800C (es)
CR (1) CR8545A (es)
EA (1) EA011159B1 (es)
EC (1) ECSP066751A (es)
GB (1) GB0402492D0 (es)
GE (1) GEP20084361B (es)
IL (1) IL177004A0 (es)
MA (1) MA28348A1 (es)
NL (1) NL1028193C2 (es)
NO (1) NO20063944L (es)
PA (1) PA8623101A1 (es)
PE (1) PE20050772A1 (es)
TW (1) TWI300066B (es)
UY (1) UY28737A1 (es)
WO (1) WO2005077935A1 (es)
ZA (1) ZA200606236B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1940842B1 (en) * 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
AU2006304305B2 (en) * 2005-10-18 2010-04-01 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
CN101426782B (zh) * 2006-02-23 2012-10-31 辉瑞股份有限公司 黑皮质素4型受体激动剂哌啶羰基吡咯烷
WO2007096763A2 (en) * 2006-02-23 2007-08-30 Pfizer Limited Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
ME01579B (me) 2007-08-07 2014-09-20 Takeda Pharmaceuticals Co Derivati pirolidin-2-ona kao modulatori androgenskih receptora
UA99555C2 (en) 2008-11-12 2012-08-27 Элджи Лайф Саенсез Лтд. Melanocortin receptor agonists
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
PL3150578T3 (pl) * 2014-05-29 2021-07-19 Mitsubishi Tanabe Pharma Corporation Nowy związek pirolidynowy i zastosowanie jako agonisty receptora melanokortyny
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
PE20180690A1 (es) 2015-04-27 2018-04-23 Intercept Pharmaceuticals Inc Composiciones de acido obeticolico y metodos de uso
EP3333165B1 (en) * 2015-08-04 2019-09-18 Astellas Pharma Inc. Piperazine derivative
CN112694436B (zh) * 2020-12-30 2022-07-08 济南周行医药科技有限公司 一种槟榔碱的合成方法
BR112023022863A2 (pt) * 2021-05-06 2024-01-23 Lg Chemical Ltd Forma cristalina vii do composto agonista do receptor de melanocortina e método para preparar o mesmo
CN114211258B (zh) * 2021-11-04 2023-09-26 江阴市大久金属科技有限公司 高精密无缝钢管制备工艺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439152C (en) * 2001-02-28 2008-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor agonists
DE60215132T2 (de) * 2001-02-28 2007-08-23 Merck & Co., Inc. Acylierte piperidin-derivate als melanocortin-4-rezeptor-agonisten

Also Published As

Publication number Publication date
PA8623101A1 (es) 2006-05-16
PE20050772A1 (es) 2005-10-31
ZA200606236B (en) 2008-04-30
JP4031814B2 (ja) 2008-01-09
KR20060127125A (ko) 2006-12-11
GEP20084361B (en) 2008-04-29
NL1028193A1 (nl) 2005-08-08
CN1930146A (zh) 2007-03-14
CA2555800A1 (en) 2005-08-25
EA200601279A1 (ru) 2006-12-29
EA011159B1 (ru) 2009-02-27
UY28737A1 (es) 2005-09-30
AU2005213538A1 (en) 2005-08-25
NL1028193C2 (nl) 2006-04-20
MA28348A1 (fr) 2006-12-01
ATE511507T1 (de) 2011-06-15
BRPI0507435A (pt) 2007-07-03
EP1716135A1 (en) 2006-11-02
KR100830763B1 (ko) 2008-05-19
CA2555800C (en) 2010-06-15
IL177004A0 (en) 2006-12-10
AP2006003699A0 (en) 2006-08-31
TW200526625A (en) 2005-08-16
CR8545A (es) 2007-09-03
AR048232A1 (es) 2006-04-12
GB0402492D0 (en) 2004-03-10
WO2005077935A1 (en) 2005-08-25
EP1716135B1 (en) 2011-06-01
NO20063944L (no) 2006-10-31
JP2007534668A (ja) 2007-11-29
TWI300066B (en) 2008-08-21

Similar Documents

Publication Publication Date Title
ECSP066751A (es) Piperidinilcarbonil-pirrolidinas y su uso como agonistas de melanocortina
ECSP11011439A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
UY30748A1 (es) Compuesto0s novedosos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CR11826A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
CR11861A (es) Compuestos organicos
HN2012001162A (es) Triazolopiridinas
UY29267A1 (es) Derivados de piperidina y su uso como agentes antiinflamatorios
ECSP088265A (es) Derivados de carboxamida como antagonistas del receptor muscarínico
UY31524A1 (es) Nuevos compuestos 010
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
PA8796201A1 (es) Agentes anti-infecciosos y su uso
CL2008002132A1 (es) Compuestos derivados de sulfonamidas, moduladores de trpm8; composiciones farmaceuticas que comprenden a dichos compuestos; y uso de dichos compuestos en el tratamiento del dolor neuropatico, dolor inflamatorio, ansiedad, depresion, hiperalgesia inflamatoria, entre otras.
UY30610A1 (es) Moduladores de mglur5
UY30976A1 (es) Nuevos derivados de quinolina, composiciones farmaccuticas que los contienen, procesos de preparacion y aplicaciones.
BRPI0913457B8 (pt) Composto e composição farmacêutica
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
ECSP055671A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesteresa
UY30808A1 (es) Derivados de benzotiazolonas, composiciones conteniéndolos y aplicaciones
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
CO6351723A2 (es) Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de crf1
NI201100015A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico.